A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

T-bet is a transcription factor, one of the control proteins in the cell nucleus that can turn specific groups of genes on ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and ...

Breakthrough Mouse Study Hints At Psychedelic Compound Yielding Possible Anti-Aging Drugs In A Nutshell Lab studies found ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A better understanding of human smell is emerging as scientists interrogate its fundamental elements: the odor molecules that ...